Who are MTX's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Methotrexate therapy, Placebo Methotrexate, MTX therapy, Methotrexate (stable dose), Methotrexate (MTX), Intrathecal Methotrexate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mtx.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MTX — Competitive Intelligence Brief

MTX (MTX) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; folate antagonist. Area: Oncology.

marketed Antimetabolite; folate antagonist Dihydrofolate reductase (DHFR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MTX (MTX) — South China Children's Leukemia Group. MTX (methotrexate) inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MTX TARGET	MTX	South China Children's Leukemia Group	marketed	Antimetabolite; folate antagonist	Dihydrofolate reductase (DHFR)
Methotrexate therapy	Methotrexate therapy	National Medical Research Center for Children's Health, Russian Federation	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)
Placebo Methotrexate	Placebo Methotrexate	AbbVie	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)
MTX therapy	MTX therapy	NYU Langone Health	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)
Methotrexate (stable dose)	Methotrexate (stable dose)	Hoffmann-La Roche	marketed	Antimetabolite; Folate antagonist	Dihydrofolate reductase (DHFR)
Methotrexate (MTX)	Methotrexate (MTX)	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	marketed	Antimetabolite; folate antagonist	Dihydrofolate reductase (DHFR)
Intrathecal Methotrexate	Intrathecal Methotrexate	Sun Yat-sen University	marketed	Antimetabolite; folate antagonist	Dihydrofolate reductase (DHFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite; folate antagonist class)

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 drug in this class
Case Comprehensive Cancer Center · 1 drug in this class
Chonnam National University Hospital · 1 drug in this class
South China Children's Leukemia Group · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
University Hospital, Montpellier · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MTX — Competitive Intelligence Brief. https://druglandscape.com/ci/mtx. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab